MedTrace Logo

Sculptra Aesthetic for the Treatment of Upper Knee Skin Laxity

NCT03487172 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-05-03

No results posted yet for this study

Summary

All subjects will receive three, single-sided injections of PLLA, performed 1 month apart.

Conditions

  • Lax Skin
  • Knee

Interventions

DEVICE

poly-L-lactic acid to right knee

Subjects will receive PLLA injections to the right knee and bacteriostatic water to the left.

DEVICE

poly-L-lactic acid to left knee

Subjects will receive PLLA injections to the left knee and bacteriostatic water to the right.

Sponsors & Collaborators

  • Galderma R&D

    collaborator INDUSTRY

  • Goldman, Butterwick, Fitzpatrick and Groff

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-04-10
Primary Completion
2019-04-17
Completion
2019-04-17
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03487172 on ClinicalTrials.gov